In 2012, Yin et al. assessed the clinical value of MRD monitoring in core-binding factor (CBF) AML by RT-qPCR in 278 patients enrolled in the United Kingdom MRC AML 15 trial [20]. This evidence concerns the gene CEBPZ and acute myeloid leukemia.